Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 68762

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Viral Infection
  • cardiac
  • Ophthalmological

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 68762

License Grant
The University grants the French Licensee three licenses to use technology to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported licensed products and to practice licensed method, in three specific fields of application.
License Property
ANN-001, a gene therapy product candidate, is designed to deliver A1AT protein in patients with A1AT deficiency.

ANN-002 is a gene therapy product candidate designed for the treatment of patients with hereditary angioedema (“HAE”).

Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling.  Hereditary angioedema (HAE) is caused by a low level or improper function of a protein called the C1 inhibitor. It affects the blood vessels. An HAE attack can result in rapid swelling of the hands, feet, limbs, face, intestinal tract, larynx (voicebox), or trachea (windpipe).

ANN-004 is a gene therapy program for the treatment of severe allergies, which cause extreme discomfort and can be fatal.

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger

Field of Use
Licensee is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases where continuous expression of a therapeutic protein may lead to meaningful clinical benefit. Annapurna’s initial programs address alpha-1 antitrypsin (“A1AT”) deficiency, hereditary angioedema, the cardiomyopathy associated with Friedreich’s ataxia, and severe allergy.

IPSCIO Record ID: 68763

License Grant
This agreement  between French parties grants the following
•An exclusive license for the research, development and sale of a drug using specific patented virus vectors for a specific commercial field;
•A non-exclusive research license for the research and development of a drug using other patented virus vectors for another commercial field.
Field of Use
Licensee is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases where continuous expression of a therapeutic protein may lead to meaningful clinical benefit. Annapurna’s initial programs address alpha-1 antitrypsin (“A1AT”) deficiency, hereditary angioedema, the cardiomyopathy associated with Friedreich’s ataxia, and severe allergy.

IPSCIO Record ID: 68761

License Grant
This agreement grants the French Licensee the following;
•An exclusive license for the research, development and sale of a drug using specific patented virus vectors for a specific commercial field (AATD field);
•An option to be granted an exclusive license for the research, development and sale of a drug using specific patented virus vectors for another specific commercial field (Allergy field)
License Property
The virus vectors are for two disease indications Alpha-1 anti-trypsin (A1AT) deficiency and Allergy.  Alpha-1 Antitrypsin Deficiency is an inherited condition that raises your risk for lung and liver disease.
Field of Use
Licensee is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases where continuous expression of a therapeutic protein may lead to meaningful clinical benefit. Annapurna’s initial programs address alpha-1 antitrypsin (“A1AT”) deficiency, hereditary angioedema, the cardiomyopathy associated with Friedreich’s ataxia, and severe allergy.

IPSCIO Record ID: 66708

License Grant
This agreement grants the French Licensee following
•An exclusive license for the research, development and sale of a drug using specific patented virus vectors for a specific commercial field;
•A non-exclusive research license for the research and development of a drug using other patented virus vectors for another commercial field;
•An option to be granted a non-exclusive license for the sale of the drugs related to the developed under the non-exclusive research license.
Field of Use
Licensee is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases where continuous expression of a therapeutic protein may lead to meaningful clinical benefit. Initial programs address alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema, the cardiomyopathy associated with Friedreich’s ataxia, and severe allergy.

IPSCIO Record ID: 3050

License Grant
The Licensor entered into a strategic partnership Agreement with the Portuguese subsidiary of the Italian pharmaceutical company that is also the Licensee, to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other therapeutic indications throughout Europe, North Africa, Middle East and Russia.

The Licensee of Portugal will pay costs associated with regulatory approval and commercialization in the Licensed territories.  In addition, the Licensor and Licensee will share equally the costs for all development activities for optional future indications developed in partnership with the Licensee.

License Property
The Licensor retains its rights to DX-88 in all other territories.

DX-88 is a specific and potent kallikrein inhibitor, for the treatment of hereditary angioedema.  Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema).

DX-88 is also being evaluated for its therapeutic potential in other AO indications acquired and ACE inhibitor-induced AOs and, through a different collaboration, is in a Phase I trial for retinal vein occlusion-induced macular oedema.  Hereditary angioedema (HAE) is an acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, the gastrointestinal tract, the genitalia, and in potentially life-threatening cases, the larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood.

IPSCIO Record ID: 25769

License Grant
A U.S company and a pharmaceutical company headquartered in Tokyo, Japan entered into a Product Development and License Agreement under which Japanese licensee will develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in Japan.
License Property
Licensor retains its rights to subcutaneous DX-88 in the U.S., where DX-88 has been approved by the U.S. Food and Drug Administration and is marketed as Kalbitor® (ecallantide)

Hereditary angioedema (HAE) is an acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, the gastrointestinal tract, the genitalia, and in potentially life-threatening cases, the larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood.

Field of Use
The rights granted apply to the healthcare industry.

Ecallantide (DX-88) is a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.

IPSCIO Record ID: 244

License Grant
The Licensor granted an exclusive worldwide License to use their proprietary Enhanzeâ„¢ technology, to the Licensee.

Additionally, Licensor has agreed not to grant to any third party rights to use rHuPH20 to develop a combination product for the prevention or treatment of hereditary angioedema (HAE), or for three additional orphan disease indications.

License Property
The Licensor's proprietary Enhanzeâ„¢ technology, is a drug delivery platform using the Licensor's recombinant human hyaluronidase enzyme (rHuPH20) technology in combination with a C1 esterase inhibitor.

The proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin.

Field of Use
The Licensee intends to apply rHuPH20 initially to develop a novel subcutaneous formulation of Cinryze for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  Licensee seeks to combine Cinryze with rHuPH20 to enhance volume independent biodistribution, and to increase the overall convenience of the therapy by allowing for a single subcutaneous injection of Cinryze.

Hereditary angioedema is a rare but serious problem with the immune system that is passed down through families. It causes swelling, particularly of the face and airways, and abdominal cramping.  HAE symptoms include episodes of edema (swelling) in various body parts including the hands, feet, face and airway.

IPSCIO Record ID: 286301

License Grant
Licensor grants the Licensee of Japan the exclusive right to commercialize BCX7353 in Japan for the prevention of HAE attacks.
License Property
BCX7353 is in drug class Oral Serine Protease Inhibitor Targeting Plasma Kallikrein (once-daily treatment).  Licensor is a biotechnology company that discovers novel, oral, small-molecule medicines.
Field of Use
The field of use is for the therapeutic area of Hereditary Angioedema or HAE.  Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema)

IPSCIO Record ID: 203245

License Grant
Licensor grants the Japanese Licensee an exclusive license under Licensors Intellectual Property, with the right to grant sublicenses, to Develop, have Developed and conduct Regulatory Activities for Compound and Product for use in Field in Licensees Territory.

Licensor grants an exclusive license under Licensor Intellectual Property, with the right to grant sublicenses, to Manufacture and have Manufactured Drug Substance and Drug Product for use by or on behalf of Licensee, its Affiliates, Sublicensees and Third Party contractors for the Development and Commercialization of Product in Field in Licensees Territory.

License Property
Compound shall mean the compound known as DX-88 (ecallantide) with the amino acid sequence.  Product shall mean any pharmaceutical product containing Compound for subcutaneous administration.

Products incorporating DX-88 is for the treatment of angioedemas.

Field of Use
Field shall mean use in the HAE or hereditary angioedema and Other Angioedema Indications.

Angioedema is an area of swelling of the lower layer of skin and tissue just under the skin or mucous membranes.  The swelling may occur in the face, tongue, larynx, abdomen, or arms and legs.  Often it is associated with hives, which are swelling within the upper skin.

IPSCIO Record ID: 44335

License Grant
The company executed an agreement with the University,  for an exclusive license to those rights the University may own in certain patents and patent applications relating to GBT440 and GBT440 analogs.
License Property
Product candidate, GBT440, is being developed as a once-daily, oral therapy for sickle cell disease, or SCD, and currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind clinical trial that we characterize as a Phase 1/2 clinical trial. GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms. In addition to GBT440 for the treatment of SCD, we are leveraging our deep scientific expertise in the chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis, and hereditary angioedema, or HAE.
Field of Use
This Agreement pertains to the drug industry.

IPSCIO Record ID: 339531

License Grant
The parties amend certain terms of the original License Agreement in light of the sublicensee agreements.

The First Amendment has been amended to include but not limited to License Product, Regulatory Exclusivity, Sublicensee Royalty Term, Sublicensee Product and Royalty payments.

License Property
Patent applications relates to a novel synthetic microdystrophin gene to make, sell and distribute products for use in the treatment of Duchene and related disease indications resulting from a lack of functional dystrophin.

Licensed Product) is amended by adding (a) Any product, apparatus, kit, composition, or component thereof (i) whose use, sale, offer for sale, or importation of which is covered, in whole or in part, by any valid claim contained in the Patent Rights or (ii) which is made by any method, procedure, process, or step which is covered, in whole or in part, by any valid claim contained in the Patent Rights; or (b) An isolated synthetic nucleic acid molecule comprising a synthetic mini-dystrophin or micro-dystrophin gene encoding a synthetic, non-full-length, dystrophin protein that is able to restore nNOS to the sarcolemma, wherein the non-full-length dystrophin protein comprises, from the N terminus to the C terminus 1. the N-terminal domain of the dystrophin protein or a modified N-terminal domain of the dystrophin protein, 11. at least two repeats of the mid-rod domain of the dystrophin protein, wherein said at least two repeats comprise R16 and Rl 7, 111. at least 2 hinge regions of the dystrophin protein, whereas said at least two hinge regions comprise HI and H4, and 1v. the cysteine-rich domain of the dystrophin protein; wherein the mini- or micro-dystrophin gene is between 5 kb to about 8 kb in length or less than 5 kb in length, respectively.

Duchenne is caused by mutations in the dystrophin gene, which result in the absence or near-absence of dystrophin protein. Dystrophin protein works to strengthen muscle fibers and protect them from daily wear and tear. Without functioning dystrophin and certain associated proteins, muscles suffer excessive damage from normal daily activities and are unable to regenerate, leading to the build-up of fibrotic, or scar, and fat tissue. Efforts are focused on our lead product candidate, SGT-001, a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patients’ muscles and improve the course of the disease. Based on our preclinical program that included multiple animal species of different phenotypes and genetic variations, as well as preliminary clinical trial biomarker results, we believe that SGT-001, has the potential to slow or even halt the progression of Duchenne, regardless of the type of genetic mutation or stage of the disease.

Sublicensee Product means any Licensed Product commercialized by Sublicensee, its affiliates or permitted sublicensees pursuant to the Collaboration and License Agreement, dated October 22, 2020, by and between Sublicensee and Licensee.

SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy designed to address the underlying genetic cause of Duchenne muscular dystrophy (Duchenne). Duchenne is caused by mutations in the dystrophin gene that result in the absence or near absence of dystrophin protein. SGT-001 is a systemically administered candidate that delivers a synthetic dystrophin gene, called microdystrophin, to the body. This microdystrophin encodes for a functional protein surrogate that is expressed in muscles and stabilizes essential associated proteins, including neuronal nitric oxide synthase (nNOS). Data from Solid’s preclinical program suggests that SGT-001 has the potential to slow or stop the progression of Duchenne, regardless of genetic mutation or disease stage.

Field of Use
Field of use is for the cure Duchenne muscular dystrophy (“Duchenne”), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Duchenne is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births.  SGT-001 is our lead gene transfer candidate and the focus of our research and development efforts. Gene transfer, a type of gene therapy, is designed to address diseases caused by mutated genes through the delivery of functional versions of those genes, called transgenes. The transgenes are then utilized by the body to produce proteins that are absent or not functional prior to treatment, potentially offering long-lasting beneficial clinical effects.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.